A Comparative Study on 5hmC Targeting Regulation of Neurons in AD Mice by Several Natural Compounds

Abstract EN

A series of studies have confirmed that DNA methylation disorder (5mC/5hmC) is closely related to the occurrence and development of some diseases, such as Alzheimer’s disease (AD).

This study aims at discovering natural compounds that could adjust and control 5-hydroxymethylcytosine (5hmC) levels and improve Alzheimer’s disease (AD) neuronal status.

Cordycepin and cordycepic acid were selected as research materials, with resveratrol as positive control.

The results of Dot Blot indicated that cordycepin, cordycepic acid, and resveratrol significantly increased the expression level of 5hmC.

Combined with qPCR results, it was revealed that cordycepin increased the expression of ten-eleven translocation (TETs) mRNA compared with the abovementioned cordycepic acid and resveratrol.

Besides, cordycepin dramatically reduced the transcription level of Apolipoprotein E (ApoE), suggesting that cordycepin might hinder the formation of NFTs (neurofibrillary tangles) and the accumulation of amyloid β-protein (Aβ) in the brain by reducing the expression of ApoE, resulting in affecting the progression of AD.

Meanwhile, the immunofluorescence (IF) staining results demonstrated that the percentage of differentiation of SHSY-5Y cells reasonably increased after the treatment of cordycepin and cordycepic acid.

Simultaneously, the length of axons and the number of dendritic branches in mouse primary neurons were substantially increased by cordycepin.

The screening results illustrated that cordycepin had a positive influence on the level of 5hmC and the morphology of neurons, and most of the effects were better compared to the positive control (resveratrol).

It indicated that cordycepin delayed the progression of neurodegenerative diseases such as AD.

However, the specific mechanism of action still needs to be further investigated.

Our research provided a foundation for further discussion about the influence of cordycepin on AD and a new idea for the pathological study of related diseases.